Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

© 2017 Elsevier B.V. This chapter on antihelminthic drugs published in the literature between January 2016 and December 2016 includes albendazole, ivermectin, levamisole, mebendazole, oxantel pamoate, praziquantel, pyrvinium, thiabendazole and tribendimidine. Observational and placebo-controlled studies involving the use of albendazole, mebendazole, praziquantel, or tribendimidine in antihelminthic therapy are reported. A dose-comparison study examining the safety of oxantel pamoate is reported. Meta-analysis assessing the safety of albendazole, thiabendazole and ivermectin in comparative trials is included. The first report of laryngeal lesions in a patient with levamisole-induced vasculitis is described. A new case of renal pathology caused by levamisole-adulterated cocaine is reported, and the clinical and histopathologic features of pyoderma gangrenosum attributed to levamisole in a cohort of abusers are described. Hepatic failure attributed to albendazole therapy is reported. The association between administration of mebendazole or pyrvinium in pregnancy and the risk of congenital malformation is explored in a large observational study. The effect of praziquantel therapy in pregnancy on the rates of in-utero fetal death and congenital anomalies is also examined. A case of angioedema in a child caused by mebendazole–cotrimoxazole–herb interaction is reported.

Original publication




Journal article

Publication Date





295 - 300